395 related articles for article (PubMed ID: 35988787)
1. The emerging roles of HDACs and their therapeutic implications in cancer.
Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
[TBL] [Abstract][Full Text] [Related]
2. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
3. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
Hamminger P; Rica R; Ellmeier W
Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
7. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
[TBL] [Abstract][Full Text] [Related]
8. Roles of Histone Acetyltransferases and Deacetylases in the Retinal Development and Diseases.
Wang J; Feng S; Zhang Q; Qin H; Xu C; Fu X; Yan L; Zhao Y; Yao K
Mol Neurobiol; 2023 Apr; 60(4):2330-2354. PubMed ID: 36637745
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase (HDACs) inhibitors: Clinical applications.
Shanmukha KD; Paluvai H; Lomada SK; Gokara M; Kalangi SK
Prog Mol Biol Transl Sci; 2023; 198():119-152. PubMed ID: 37225317
[TBL] [Abstract][Full Text] [Related]
10. The role of histone deacetylases (HDACs) in human cancer.
Ropero S; Esteller M
Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
[TBL] [Abstract][Full Text] [Related]
11. Targeting the acetylation signaling pathway in cancer therapy.
Dang F; Wei W
Semin Cancer Biol; 2022 Oct; 85():209-218. PubMed ID: 33705871
[TBL] [Abstract][Full Text] [Related]
12. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Expression and Role of Histone Acetylation and Deacetylation in Dental Pulp Cells.
Yamauchi Y; Duncan HF
Methods Mol Biol; 2023; 2588():279-293. PubMed ID: 36418694
[TBL] [Abstract][Full Text] [Related]
14. HDAC Inhibitors.
Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies.
Slaughter MJ; Shanle EK; Khan A; Chua KF; Hong T; Boxer LD; Allis CD; Josefowicz SZ; Garcia BA; Rothbart SB; Strahl BD; Davis IJ
Cell Rep; 2021 Jan; 34(3):108638. PubMed ID: 33472068
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
Li Z; Zhu WG
Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
[TBL] [Abstract][Full Text] [Related]
18. Nonhistone protein acetylation as cancer therapy targets.
Singh BN; Zhang G; Hwa YL; Li J; Dowdy SC; Jiang SW
Expert Rev Anticancer Ther; 2010 Jun; 10(6):935-54. PubMed ID: 20553216
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Collier CD; Getty PJ; Greenfield EM
Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
[TBL] [Abstract][Full Text] [Related]
20. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]